Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for relapsing polymyalgia rheumatica
NL-OMON53470Phase 3Recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in polymyalgia rheumatica (PMR) comparing Rituximab + prednisolone taper with Placebo + prednisolone taper (2 arms). Primary endpoint: Glucocorticoid-free remission at 1 year. Started Feb 2023; status: recruiting.
02
Drugs
rituximab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON53470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53470.